Neodolpasse (Diclofenac Sodium, Orphenadrine Citrate)

Neodolpasse combines an NSAID and a muscle relaxant, acting on inflammatory pathways and skeletal muscle spasm.

• Pain: Provides analgesic relief by reducing inflammatory mediators and decreasing muscle tension.
• Inflammation: Decreases prostaglandin synthesis to control swelling in acute musculoskeletal conditions.
• Muscle spasm: Relieves skeletal muscle spasm through central anticholinergic activity, improving mobility.

• Diclofenac sodium inhibits cyclooxygenase (COX‑1 and COX‑2) enzymes, lowering prostaglandin production and thereby reducing pain and inflammation. Orphenadrine citrate acts as a centrally acting anticholinergic and histamine‑H1 antagonist, decreasing neuronal excitability and relaxing skeletal muscle fibers. The combined effect provides both anti‑inflammatory analgesia and muscle relaxation in a single intravenous preparation.

Neodolpasse may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: Mild gastrointestinal upset occurring in some patients.
• Headache: Transient headache reported after infusion.
• Dizziness: Light‑headed sensation that usually resolves quickly.
• Injection site pain: Local discomfort at the site of administration.
• Flushing: Warmth and reddening of the skin.
• Dry mouth: Reduced salivation during therapy.

Serious or Rare Side Effects

• Gastrointestinal ulcer or bleeding: Potential for serious bleeding in the stomach or intestines.
• Hepatic enzyme elevation: Possible liver function abnormalities requiring monitoring.
• Renal impairment: Decreased kidney function, especially in at‑risk patients.
• Severe allergic reactions (anaphylaxis): Rapid onset of rash, swelling, and respiratory distress.
• Cardiac arrhythmia: Irregular heart rhythm in susceptible individuals.
• Neutropenia: Low white‑blood‑cell count that can increase infection risk.

Before initiating Neodolpasse, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

• Renal function: Assess baseline renal function and monitor during therapy.
• Hepatic function: Avoid in patients with severe liver disease or monitor liver enzymes closely.
• Cardiovascular risk: Use cautiously in patients with a history of myocardial infarction or stroke.
• Bleeding risk: Avoid concomitant use with anticoagulants unless medically necessary.
• Pregnancy and lactation: Use only if benefits outweigh risks; consult a specialist.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Neodolpasse can interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased bleeding risk.
• Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity.
• Lithium: diclofenac may raise lithium serum concentrations.
• MAO inhibitors: risk of hypertensive crisis when combined with orphenadrine.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may reduce renal function when used together.
• Diuretics: potential for enhanced renal impairment.
• Corticosteroids: increased risk of gastrointestinal ulceration.